TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) insider Anil P. Ranganath sold 703 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $135.21, for a total value of $95,052.63. Following the completion of the sale, the insider now owns 8,809 shares of the company’s stock, valued at $1,191,064.89. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
TransMedics Group Stock Up 0.6 %
Shares of NASDAQ TMDX opened at $162.89 on Monday. The company has a market cap of $5.43 billion, a price-to-earnings ratio of -479.09 and a beta of 1.99. The company has a current ratio of 9.37, a quick ratio of 8.76 and a debt-to-equity ratio of 2.67. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $171.98. The stock has a 50-day moving average price of $145.56 and a two-hundred day moving average price of $114.01.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm’s quarterly revenue was up 117.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.03) EPS. As a group, analysts forecast that TransMedics Group, Inc. will post 1.1 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
TMDX has been the subject of a number of recent analyst reports. TD Cowen upped their target price on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Cantor Fitzgerald initiated coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They set an “overweight” rating and a $161.00 price objective for the company. JPMorgan Chase & Co. increased their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Piper Sandler boosted their target price on shares of TransMedics Group from $170.00 to $180.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Finally, Stephens increased their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average target price of $166.88.
Get Our Latest Stock Report on TransMedics Group
TransMedics Group Company Profile
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Stories
- Five stocks we like better than TransMedics Group
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Upcoming IPO Stock Lockup Period, Explained
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- About the Markup Calculator
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.